QUOTED. 23 April 2021. Thomas Schinecker.
In its first quarter 2021 sales earnings report, Roche highlighted the strength of its diagnostics business as biosimilars cannibalize its pharmaceutical revenues. CEO Thomas Schinecker said the growth should continue.
“As more test supply is available, and testing needs go down, people will try to consolidate their own automated platforms. No other company is as well positioned as Roche in this aspect. We have the strongest automated platform.” – Thomas Schinecker, CEO, Roche Diagnostics
- Find out more: Diagnostics Saves Roche From Q1 Difficulties
Click here for a free trial of Medtech Insight